US/UK/Canada

Share

Quotes

When I use the Össur POWER KNEE, I feel like I have my knee back.
Prosthetist John Arnold, who lost his limb in 2022 after a motorcycle accident
Pick a time period -
Tags ( Active)

Embla Medical hf: Conference call details for Q4/FY 2024

Reykjavik, Iceland/Copenhagen, Denmark, January 9, 2025. Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q4/Full Year 2024 Report on 5 February 2025 at 7:00 CET. A conference call will be hosted on the same day at 9:00 CET / 8:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly and full year results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors

Embla Medical: Financial Calendar 2025

Announcement no. 13/2024 Reykjavik, Iceland/Copenhagen, Denmark, December 6, 2024. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today published its financial calendar for 2025. Financial Calendar 2025 5 February 2025                       Interim Report Q4 2024/2024 Annual Report 12 March 2025                         2025 Annual General Meeting 29 April 2025                            Interim Report Q1 2025 22 July 2025                             Interim Report Q2 2025 21 October 2025

Embla Medical hf: Interim Report Q3 2024

Announcement no. 12/2024 Interim report Q3 2024 22 October 2024 Sveinn Sölvason, President and CEO, comments: “We delivered solid sales in the third quarter amounting to USD 214 million. Organic sales growth was 7% and local currency growth was 11%. The strong momentum we have seen in EMEA throughout 2024 continued driven by strong performance in Prosthetics & Neuro Orthotics and Patient Care. In our Bracing & Supports business growth was more modest for the quarter. As of September 1, 2024, US Medicare has expanded access to advanced bionics for K2 patients. Healthcare

Embla Medical hf: Conference call details for Q3 2024

Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q3 2024 Interim Report on October 22, 2024, at 7:00 CET. A conference call will be hosted on the same date at 9:00 CET / 7:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: http://www.emblamedical.com/investors The conference call webcast can be accessed through following link:

Para Athletes Using Össur Mobility Solutions Win 22 Medals in Paris

Össur Athletes Also Set 5 New Paralympic Records While Wearing "Gold Standard" Cheetah Prosthetic BladesREYKJAVIK, ICELAND, September 11, 2024 - A global team of elite para athletes who wear Össur’s renowned prosthetics won 22 medals and set five new Paralympic Records during the 2024 Paralympic Games in Paris, with the company’s iconic carbon fiber Cheetah sports blades, easily identified by their distinctive yellow stripe, dominating several categories of Athletics competition.   In all, members of Team Össur and Össur Ambassadors delivered championship performances in several Long

Embla Medical hf: Interim Report Q2 2024

· Delivering our highest ever quarterly sales amounting to USD 217 million · Organic growth of 6% for Q2 driven strong performance in Prosthetics & Neuro Orthotics and Patient Care · EBITDA was USD 47 million and EBITDA margin was 22% for Q2 · Medicare in the US has finalized a proposal that grants active K2 patients access to prosthetic knees · New exciting innovation launched in bionics with NAVii[®] by Össur and Icon[®] by College ParkAnnouncement no. 11/2024 Interim report Q2 2024 23 July 2024 Sveinn Sölvason, President and CEO, comments: “We delivered our

Embla Medical hf: The Centers for Medicare & Medicaid Services (CMS) grants extended coverage in the U.S. for lower-limb active K2 amputee patients to access bionic prosthetic solutions

Reykjavik, Iceland/Copenhagen, Denmark, July 18, 2024. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that the Centers for Medicare & Medicaid Services has finalized a proposal that will expand patients access to high activity K3 knees in the United States. The proposal enables a large patient group of active K2[1][ ]functional level amputees to gain access to bionic knee technology. Previously, Medicare had restricted access to these knees to only high-active amputees classified as functional level K3 and K4. The

Embla Medical hf: Conference call details for Q2 2024

9 July 2024 Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q2 2024 Interim Report on 23 July 2024 at 7:00 CET. A conference call will be hosted on the same date at 9:00 CET / 7:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: http://www.emblamedical.com/investors The conference call webcast can be accessed through

Embla Medical hf: Interim Report Q1 2024

Announcement no. 10/2024 Interim report Q1 2024 23 April 2024 Sveinn Sölvason, President and CEO, comments: “Sales growth was strong in the first quarter or 10% and organic growth was 7%, driven by volume growth in Prosthetics & Neuro Orthotics and Patient Care. Growth was driven by a strong performance in EMEA, but the year started off slowly in Americas and APAC. Financial performance of FIOR & GENTZ, which we acquired in January, was strong in the first quarter post-acquisition and work has begun to leverage our global sales infrastructure to harvest commercial synergies.

Össur hf: Board Decisions Following the Annual General Meeting

Announcement no. 9/2024 13 March 2024 Board Decisions Following the Annual General Meeting Below are the Board decisions following the Annual General Meeting of Össur hf. held today, Wednesday 13 March 2024. Allocation of responsibilities within the Board of Directors Following the Company’s Annual General Meeting today, Mr. Niels Jacobsen was re-elected as Chairman of the Board of Directors and Dr. Svafa Grönfeldt was re-elected as Vice Chairman. Mr. Arne Boye Nielsen, Dr. Alberto Esquenazi and Ms. Caroline Vagner Rosenstand were appointed to the Audit Committee.

Össur hf: Results of the Annual General Meeting

Announcement no. 8/2024 13 March 2024 Results of the Annual General Meeting Enclosed are the results of the Annual General Meeting of Össur hf. held today, Wednesday 13 March 2024. Further information David Hreidarsson, VP of Investor Relations, IR@ossur.com, +354 661 8225 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®. For over 50 years, Össur has

Össur hf: Candidates to the Board of Directors

Announcement no. 7/2024 10 March 2024 Candidates to the Board of Directors Enclosed are details on the candidates to the Board of Directors of Össur hf., to be elected at the Annual General Meeting held on Wednesday 13 March 2024 at 9:00 AM (GMT) at the Company’s headquarters at Grjótháls 5, Reykjavík, Iceland. It should be noted that the Board of Directors proposes to amend to the Company’s Articles of Association so that the Board is composed of 4-7 individuals instead of 5. The Board of Directors proposes that 6 individuals are elected at the Annual General Meeting for the

Össur hf: Final Agenda and Proposals for the Annual General Meeting 13 March 2024

Announcement no. 6/2024 28 February 2024 Final agenda and proposals for the Annual General Meeting 13 March 2024 Enclosed is the final agenda and proposals for Össur hf.'s Annual General Meeting to be held on Wednesday 13 March 2024 at 9:00 AM (GMT) at the Company’s headquarters at Grjótháls 5, Reykjavík, Iceland. No changes have been made to the previously announced agenda and proposals. Further information David Hreidarsson, VP of Investor Relations, IR@ossur.com, +354 661 8225 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail,

Össur hf: Össur establishes new parent organization to be named Embla Medical

Investor News 21 February 2024 Össur establishes new parent organization to be named Embla Medical Össur proposes to establish a new parent organization to be named Embla Medical, which will become the listed company. This change will formally be implemented by changing the name of the Össur hf. entity to Embla Medical hf. Over the years the Company has evolved and now operates across the whole value chain, serving individuals with chronic mobility challenges in need of prosthetics, neuro orthotics and bracing solutions. Today the Company operates several product and patient

Össur hf: Annual General Meeting 13 March 2024

Announcement no. 5/2024 21 February 2024 Annual General Meeting 13 March 2024 Össur hf.'s Annual General Meeting will be held on Wednesday 13 March 2024 at 9:00 AM (GMT) at the Company’s headquarters at Grjótháls 5, Reykjavík, Iceland. Enclosed is the convocation, which includes the proposed agenda for the Annual General Meeting and information on shareholders’ participation and registration, shareholders’ rights, voting and proxies, and other practical matters, as well as the proposed resolutions and remarks on each item on the agenda. Further information David

Össur climate targets validated by the Science Based Targets initiative

Össur, a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®, announced today that the company‘s emissions reduction targets have been validated by the Science Based Targets initiative (SBTi).Össur commits to reducing absolute Scope 1 and 2 greenhouse gas emissions by 79% by 2030 from a 2019 base year. Össur also commits to reducing absolute Scope 3 greenhouse gas emissions from purchased goods and services, fuel and energy-related activities, upstream and downstream transportation and distribution by 25% by 2030 from a 2021 base year.

Össur hf: Annual Report 2023

Announcement no. 4/2024 Annual Report 2023 30 January 2024 Annual Report 2023 Össur’s Annual Report 2023 has just been published and is available for download at the link below. An online version of the Annual Report 2023 is available at https://annual-report.ossur.com/ Further information David Hreidarsson, VP of Investor Relations, IR@ossur.com, +354 661 8225 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur (Nasdaq Copenhagen: OSSR) is a leading global

Össur hf: Interim Report Q4 2023

Announcement no. 3/2024 Interim report Q4 2023 30 January 2024 Sveinn Sölvason, President and CEO, Comments: “I’m very pleased to end the year on a solid quarter with organic growth of 9%, driven by continued strong performance in Prosthetics and Patient Care. Organic growth for the full year was 9% and in 2023 we have grown the business in all regions and business segments. We reached a major milestone in our journey to become an increasingly patient focused company, addressing chronic mobility challenges in a broader context, by acquiring FIOR & GENTZ in January 2024. With the

Össur hf: Össur’s total share capital following completion of capital increase of 6,636,122 shares

Announcement no. 2/2024 24 January 2024 Background Reference is made to Össur’s announcement no. 1/2024 published 16 January 2024. In connection with the acquisition of Fior & Gentz, the Board of Directors of Össur resolved to utilize the authorization in Article 5, paragraph 1, of the Articles of Association to issue 6,636,122 new shares in Össur. The price of each new share was DKK 28.10 and the total value of the share capital increase was thus DKK 186 million (EUR 25 million). The sellers of Fior & Gentz subscribed for all the new shares. The sellers agreed to a one-year

Össur hf: Össur acquires FIOR & GENTZ

Announcement no. 1/2024 16 January 2024 Össur acquires FIOR & GENTZ Össur, a leading global provider of innovative mobility solutions, has signed an agreement to acquire all shares of privately owned Fior & Gentz, a leading maker of lower limb neuro orthotic components. Fior & Gentz develops and distributes knee and ankle orthotic joints to create innovative custom-made orthotics for patients with gait impairment due to neurological conditions. Fior & Gentz was founded in 1997 in Germany and employs around 80 people. In 2023, Fior & Gentz reached total sales of approx. EUR 21

Össur hf: Financial Calendar 2024

Announcement no. 18/202320 December 2023 Össur’s financial calendar 2024 30 January 2024  Interim report Q4 2023 and Annual Report 202313 March 2024  Annual General Meeting23 April 2024  Interim report Q1 202423 July 2024  Interim report Q2 202422 October 2024  Interim report Q3 20245 February 2025  Interim report Q4 2024 and Annual Report 202412 March 2025  Annual General Meeting Further information David Hreidarsson, VP of Investor Relations, IR@ossur.com, +354 661 8225 Össur press releases by e-mail If you wish

Össur hf: Major Shareholder Announcement

Announcement no. 17/2023 21 November 2023 Please find enclosed a major shareholder announcement. Further information David Hreidarsson, VP of Investor Relations, IR@ossur.com, +354 661 8225 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur (Nasdaq Copenhagen: OSSR) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®. For over 50 years, Össur has had a strong purpose rooted in positively impacting people’s

Össur hf: Interim report Q3 2023

Announcement no. 16/2023 Interim report Q3 2023 24 October 2023 Sveinn Sölvason, President and CEO, Comments: “Sales amounted to 193 million, with 7% organic growth, and the EBITDA margin was 19% in Q3 2023. Organic growth was 9% in the first nine months, driven by a strong contribution in all our business segments and regions. We continue to be on track to deliver on our ambition to grow 7-10% in average local currency growth in 2023-2027, in line with our recently launched Growth’27 strategy. We see strong volume growth within Prosthetics and Patient Care, and I am pleased to

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media